### Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains

4	James Brett Case <sup>1</sup> , Samantha Mackin <sup>1,2</sup> , John Errico <sup>2</sup> , Zhenlu Chong <sup>1</sup> , Emily A. Madden <sup>1</sup> ,
5	Barbara Guarino <sup>3</sup> , Michael A. Schmid <sup>3</sup> , Kim Rosenthal <sup>4</sup> , Kuishu Ren <sup>4</sup> , Ana Jung <sup>2</sup> , Lindsay
6	Droit <sup>5</sup> , Scott A. Handley <sup>2</sup> , Peter J. Halfmann <sup>6</sup> , Yoshihiro Kawaoka <sup>6,7,8</sup> , James E. Crowe, Jr. <sup>9,10,11</sup> ,
7	Daved H. Fremont <sup>2,5,12</sup> , Herbert W. Virgin <sup>2,13,14</sup> , Yueh-Ming Loo <sup>4</sup> , Mark T. Esser <sup>4</sup> , Lisa A.
/	
8	Purcell <sup>13</sup> , Davide Corti <sup>3</sup> , and Michael S. Diamond <sup>1,2,5,15,16</sup>
9	
10	<sup>1</sup> Department of Medicine, Washington University School of Medicine, St. Louis, MO.
11	<sup>2</sup> Department of Pathology & Immunology, Washington University School of Medicine, St.
12	Louis, MO.
13	<sup>3</sup> Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
14	<sup>4</sup> Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD.
15	<sup>5</sup> Department of Molecular Microbiology, Washington University School of Medicine, St. Louis,
16	MO.
17	<sup>6</sup> Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary
18	Medicine, University of Wisconsin-Madison, Madison, WI.
19	<sup>7</sup> Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
20	<sup>8</sup> The Research Center for Global Viral Diseases, National Center for Global Health and
21	Medicine
22	Research Institute, Tokyo, Japan.
23	<sup>9</sup> Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN.
24	<sup>10</sup> Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
25	<sup>11</sup> Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical
26	Center, Nashville, TN.
27	<sup>12</sup> Department of Biochemistry & Molecular Biophysics, Washington University School of
28	Medicine, St. Louis, MO.

- <sup>13</sup>Vir Biotechnology, San Francisco, CA.
- 30 <sup>14</sup>University of Texas Southwestern Medical Center, Dallas, TX.
- 31 <sup>15</sup>Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy
- 32 Programs, Washington University School of Medicine, Saint Louis, MO.
- <sup>16</sup>Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of
- 34 Medicine, Saint Louis, MO.
- 35
- 36 *†* **Corresponding author:** Michael S. Diamond, M.D., Ph.D., mdiamond@wustl.edu

#### 37 ABSTRACT

38 Omicron variant strains encode large numbers of changes in the spike protein 39 compared to historical SARS-CoV-2 isolates. Although in vitro studies have suggested that several monoclonal antibody therapies lose neutralizing activity against Omicron variants<sup>1-</sup> 40 41 <sup>4</sup>, the effects *in vivo* remain largely unknown. Here, we report on the protective efficacy 42 against three SARS-CoV-2 Omicron lineage strains (BA.1, BA.1.1, and BA.2) of two 43 monoclonal antibody therapeutics (S309 [Vir Biotechnology] monotherapy and AZD7442 44 [AstraZeneca] combination), which correspond to ones used to treat or prevent SARS-45 CoV-2 infections in humans. Despite losses in neutralization potency in cell culture, S309 or AZD7442 treatments reduced BA.1, BA.1.1, and BA.2 lung infection in susceptible mice 46 47 that express human ACE2 (K18-hACE2). Correlation analyses between in vitro 48 neutralizing activity and reductions in viral burden in K18-hACE2 or human FcyR 49 transgenic mice suggest that S309 and AZD7442 have different mechanisms of protection 50 against Omicron variants, with S309 utilizing Fc effector function interactions and 51 AZD7442 acting principally by direct neutralization. Our data in mice demonstrate the 52 resilience of S309 and AZD7442 mAbs against emerging SARS-CoV-2 variant strains and 53 provide insight into the relationship between loss of antibody neutralization potency and 54 retained protection in vivo.

#### 56 MAIN TEXT

57 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant strains continue 58 to emerge and spread globally despite currently employed countermeasures and public health 59 mandates. Since late 2020, variants of concern (VOC) and interest (VOI) have arisen due to 60 continued SARS-CoV-2 evolution. Many variants contain substitutions in the N-terminal domain 61 (NTD) and the receptor binding motif (RBM) of the receptor binding domain (RBD). Omicron 62 lineage variants containing the largest numbers of spike protein changes described so far have 63 emerged, spread globally, and become dominant. Moreover, cell-based studies suggest that the 64 neutralizing activity of many monoclonal antibodies (mAbs) with Emergency Use Authorization 65 (EUA) status or in advanced clinical development is diminished or abolished against Omicron lineage strains (BA.1, BA.1.1, and BA.2)<sup>1,2,5,6</sup>. However, the effect of mutations that compromise 66 67 antibody neutralization on their efficacy in vivo against SARS-CoV-2 remains less clear. Indeed, for some classes of broadly neutralizing mAbs against influenza<sup>7,8</sup> and Ebola<sup>9,10</sup> viruses, there is 68 69 no strict correlation between neutralizing activity *in vitro* and protection in animal models. Here, 70 using mAbs that are currently in use to prevent or treat SARS-CoV-2 infection, we evaluated 71 how the antigenic shift in Omicron variants affects neutralization in cells and protection in mice.

72

#### 73 MAb neutralization against Omicron lineage viruses

We analyzed the substitutions in the RBDs of BA.1 (B.1.1.529), BA.1.1 (B.1.1.529 R346K), and BA.2 strains (**Fig. 1a, Extended Data Fig. 1**) in the context of the structurallydefined binding epitopes of S309, a cross-reactive SARS-CoV mAb and the parent of Sotrovimab [VIR-7831], and AZD8895 and AZD1061, two mAbs that together (AZD7442) form the clinically-used Evusheld combination treatment (**Fig. 1b-e, Extended Data Fig. 1**). S309

binds a conserved epitope on the RBD that is spatially distinct from the RBM<sup>11</sup> and the
AZD8895 and AZD1061 antibodies bind non-overlapping RBM epitopes<sup>12</sup>. Across Omicron
lineage strains, substitutions at several antibody contact residues have occurred (S309: G339D,
R346K, N440K; AZD8895: K417N, S477N, T478K, E484A, Q493R; AZD1061: R346K,
N440K, E484A, Q493R).

84 Because of these sequence changes, we assessed the neutralizing activity of S309, 85 AZD8895, AZD1061, and AZD7442 against BA.1, BA.1.1, and BA.2 viruses in Vero-86 TMPRSS2 cells. For these studies, we used mAbs that correspond to the products in clinical use 87 which have Fc modifications: S309-LS [M428L/N434S], AZD8895-YTE/TM 88 [M252Y/S254T/T256E and L234F/L235E/P331S], AZD1061-YTE/TM, and AZD7442-89 YTE/TM. The LS and YTE Fc substitutions result in extended antibody half-life in humans, and the TM changes reduce Fc effector functions<sup>13</sup>. Compared to the historical WA1/2020 D614G 90 91 strain (hereafter D614G), antibody incubation with BA.1 was associated with 2.5-fold (S309-92 LS), 25-fold (AZD7442-YTE/TM), 118-fold (AZD8895-YTE/TM), and 206-fold (AZD1061-93 YTE/TM) reductions in neutralization potency (Fig. 1f-o), which agree with experiments with authentic or pseudotyped SARS-CoV-2<sup>1,2,5,6</sup>. Some differences were observed with BA.1.1: 94 95 whereas S309-LS and AZD8895-YTE/TM were only slightly less effective against BA.1.1 96 compared to BA.1, the neutralizing activity of AZD1061-YTE/TM was reduced by almost 97 1,700-fold. Despite the decrease in activity of the AZD1061-YTE/TM component, the 98 AZD7442-YTE/TM combination still showed inhibitory activity against BA.1.1 with a 176-fold 99 reduction compared to D614G. Whereas small (no change to 5-fold) reductions in neutralization 100 activity were observed with AZD1061-YTE/TM and AZD7442-YTE/TM against BA.2, larger 101 reductions (32- and 68-fold) were observed for S309-LS and AZD8895-YTE/TM compared to

102 D614G. Overall, these data demonstrate that S309 retains potency against BA.1 and BA.1.1 103 strains but has less *in vitro* neutralizing activity against BA.2, and the AZD7442 combination 104 shows reduced yet residual activity against strains from all three Omicron lineages.

- 105
- 106

#### 6 MAb protection *in vivo* against Omicron viruses

107 Because S309 and AZD7442 mAbs might act in vivo by a combination of mechanisms 108 that are not fully reflected by *in vitro* neutralization potency assays, we evaluated the effects of 109 the mutations observed in BA.1, BA.1.1 and BA.2 on efficacy in animals. For these studies, we 110 used S309-LS and a different form of AZD7442, which contained only the TM substitutions and 111 not the YTE modification. Although the YTE modification promotes antibody recycling to 112 confer extended antibody half-life in humans and non-human primates, it accelerates antibody elimination in rodents<sup>14</sup>. To assess the efficacy of S309-LS and AZD7442-TM in vivo, we 113 114 administered a single 200 µg (~10 mg/kg total) mAb dose to K18-hACE2 transgenic mice by 115 intraperitoneal injection one day prior to intranasal inoculation with BA.1, BA.1.1, or BA.2 116 strains. Although Omicron lineage viruses are less pathogenic in mice, they still replicate to high levels in the lungs of K18-hACE2 mice<sup>15</sup>. Nonetheless, as preliminary studies suggested slightly 117 118 different kinetics of replication and spread in mice, we harvested samples at 7 dpi for BA.1 and BA.1.1 and 6 dpi for BA.2<sup>16</sup>. In BA.1 and BA.1.1-infected mice, S309-LS mAb reduced viral 119 120 burden in the lung, nasal turbinates, and nasal washes at 7 dpi compared to isotype mAb-control 121 treated mice (Fig. 2a-d). Nonetheless, control of infection, as judged by viral RNA levels, was 122 less efficient against BA.1 (182-fold reduction) and BA.1.1 (39-fold reduction) viruses than 123 against D614G (>500,000-fold reduction). Despite the diminished neutralizing activity against 124 BA.2 in vitro, S309-LS treatment reduced viral RNA levels in the lungs of BA.2-infected mice

125 substantially (742-fold reduction) (Fig 2a, b). Protection by S309-LS was not observed in the 126 nasal turbinates or nasal washes of mice challenged with BA.2 (Fig. 2c, d), in part due to the low 127 and variable levels of infection with this variant. AZD7442-TM treatment differentially reduced 128 viral burden in the lungs of mice against D614G (>400,000-fold reduction in viral RNA), BA.1 129 (91-fold reduction in viral RNA), BA.1.1 (4-fold reduction in viral RNA), and BA.2 (>100,000-130 fold reduction in viral RNA) (Fig. 2e, f). Protection in the upper respiratory tract was less 131 consistent, as AZD7442-TM treatment lowered viral RNA levels in the nasal washes of D614G 132 and BA.1-infected mice but not in BA.1.1 or BA.2-infected mice and failed to reduce D614G, 133 BA.1, BA.1.1, or BA.2 infection in the nasal turbinates (Fig. 2g, h). 134 As an independent metric of mAb protection, we measured cytokine and chemokine 135 levels in the lung homogenates of S309-LS and AZD7442-TM treated animals infected with 136 Omicron variant strains (Fig 2i-j, and Extended Data Fig. 2, 3). All infected K18-hACE2 mice 137 receiving isotype control mAbs had increased expression levels of several pro-inflammatory 138 cytokines and chemokines such as G-CSF, GM-CSF, IFN- $\gamma$ , IL-1 $\beta$ , IL-6, CXCL-10, CCL-2, and 139 CCL-4 when compared to uninfected mice. In contrast, mice treated with AZD7442-TM mAbs 140 and infected with BA.1 or BA.2 but not BA.1.1. showed reduced levels of pro-inflammatory 141 cytokines and chemokines, which is consistent with effects on viral burden (Fig. 2e, f). In 142 comparison to the isotype controls, mice treated with S309-LS had lower levels of cytokines and 143 chemokines in lung homogenates after infection with all three Omicron variants, although the 144 protection against BA.2-induced inflammation was less than against BA.1. or BA.1.1. Overall, 145 these experiments suggest that despite losses in neutralizing potency in cell culture, S309-LS or 146 AZD7442-TM can limit inflammation in the lung caused by Omicron variants.

147 We next evaluated whether the differences in neutralizing activity of S309-LS and 148 AZD7442-YTE/TM correlated with lung viral burden after infection with the three Omicron 149 strains. The change in AZD7442-YTE/TM neutralizing activity associated directly with the 150 differences in lung viral burden of each Omicron variant (Fig. 2k). This relationship is consistent with its likely mechanism of action, virus neutralization and inhibition of entry<sup>17,18</sup>. The 151 152 AZD7442-TM version we used, like the clinical drug Evusheld, encodes for modifications in the 153 constant region of the mAb heavy chains that profoundly decrease binding to Fc-gamma receptors (FcyRs) and complement components (<sup>19</sup> and Fig 3a). In comparison, for S309-LS, a 154 155 similar direct correlation between changes in neutralization potency in vitro and reductions in 156 viral burden in vivo was not observed (Fig. 21), indicating a possible additional protective 157 mechanism beyond virus neutralization.

158

#### 159 S309-LS employs Fc effector functions to protect against SARS-CoV-2 variants

160 To evaluate a potential role for Fc effector functions in S309 mAb-mediated protection 161 against Omicron strains, we engineered loss-of-function GRLR mutations (G236R, L328R) into 162 the Fc domain of the human IgG1 heavy chain of S309; these substitutions eliminate antibody 163 binding to FcyRs<sup>13</sup>. Introduction of the GRLR mutations abrogated binding to hFcyRI and 164 hFcyRIIIa, as expected (Fig. 3a) but did not affect neutralization of the SARS-CoV-2 strains 165 (Extended Data Fig. 4). Next, we compared VIR-7831 (the clinical form of S309-LS) and 166 S309-GRLR in an *in vitro* antibody-dependent cell cytotoxicity (ADCC) assay. When target cells 167 expressing similar levels of Wuhan-D614, BA.1, or BA.2 spike proteins on the cell surface (Fig. 168 **3b**) were incubated with VIR-7831 mAb, we observed some reductions in binding to Omicron spike proteins compared to mAb S2X324, an antibody that retains neutralizing activity against 169

BA.1, BA.1.1, and BA.2 and engages a distinct epitope in the RBM<sup>4</sup>. Despite the differences in 170 171 binding, target cells expressing Wuhan-D614, BA.1, or BA.2 spike proteins were lysed 172 efficiently by primary natural killer (NK) cells (antibody-dependent cellular cytotoxicity, 173 ADCC) isolated from four donors by VIR-7831 but not by S309-GRLR (Fig. 3c, d, Extended 174 **Data Fig. 5**). Similarly, primary CD14<sup>+</sup> monocytes isolated from five donors mediated 175 comparable antibody-dependent cellular phagocytosis (ADCP) of target cells expressing Wuhan-176 D614, BA.1, or BA.2 spike proteins by VIR-7831 but not by S309-GRLR (Fig. 3e, f, Extended 177 Data Fig. 6, 7).

178 To evaluate the role of effector functions in vivo in S309-LS mAb-mediated protection 179 against Omicron variant strains, we treated K18-hACE2 mice with a single 200 µg (~10 mg/kg 180 total) dose of S309-GRLR mAb by intraperitoneal injection one day prior to intranasal 181 inoculation with D614G, BA.1, or BA.2 strains. At 6 (BA.2) or 7 (D614G and BA.1) dpi, viral 182 RNA levels in the lungs, nasal turbinates, and nasal washes were measured (Fig. 3g-i). Although 183 S309-GRLR treatment reduced viral burden in the lung and nasal turbinates of D614G-infected 184 mice, it did not limit infection by BA.1 and BA.2 strains in the tissues tested. To corroborate these findings, we treated human  $Fc\gamma R$  (hFc $\gamma R$ ) transgenic C57BL/6 mice<sup>20</sup> with a single 3 185 186 mg/kg dose of S309-LS or S309-GRLR mAbs one day prior to inoculation with a SARS-CoV-2 187 Beta (B.1.351) isolate; we used the Beta isolate for these studies because Omicron strains replicate poorly in conventional C57BL/6 mice lacking expression of hACE2<sup>16</sup>. At 2 or 4 dpi. 188 189 S309-LS mAb-treated hFcyR mice showed markedly reduced levels of viral RNA (49 to 127-190 fold) or infectious virus (56- to 538-fold) in the lung compared to the isotype control-treated 191 mice, whereas animals administered S309-GRLR showed smaller (2.3- to 13-fold) differences, 192 most of which did not attain statistical significance (Fig. 3j, k). Collectively, these data suggest

193 that the protection mediated by S309-LS mAb *in vivo* is mediated at least in part by Fc effector 194 functions and engagement of  $Fc\gamma Rs$ .

#### 195 **DISCUSSION**

196 Due to the continued emergence of SARS-CoV-2 variants encoding an increasing 197 number of amino acid changes in the spike protein, antibody countermeasure efficacy requires 198 continued monitoring. When the BA.1 Omicron virus emerged in late 2021, five mAb therapies 199 were in late-stage clinical development or had acquired EUA status. In vitro assays with pseudoviruses<sup>5</sup> and authentic viruses<sup>1</sup> established that mAb therapies from Regeneron 200 201 (REGN10933 and REGN10987), Lilly (LY-CoV555 and LY-CoV016), and Celltrion (CT-P59) 202 showed a complete loss in neutralizing activity against BA.1. Subsequent experiments in K18-203 hACE2 mice confirmed that the REGN-COV2 mAb cocktail completely lost its efficacy against the BA.1 variant<sup>21</sup>. More recently, an additional antibody (LY-CoV1404, bebtelovimab), which 204 205 shows considerable neutralization activity against a range of SARS-CoV-2 strains, received EUA 206 status<sup>22</sup>, although protection data *in vivo* against VOC, including Omicron, has not yet been 207 published.

208 We compared the in vitro neutralizing activity and in vivo efficacy of S309 (parent mAb 209 of Sotrovimab) and AZD7442 (Evusheld) that correspond to the clinically-used products. Our 210 study establishes the utility of S309 and AZD7442 mAbs against highly divergent SARS-CoV-2 211 variants. Despite losses in neutralization potency against BA.1, BA.1.1, and BA.2 strains, S309-212 LS and AZD7442-TM reduced viral burden and pro-inflammatory cytokine levels in the lungs of 213 K18-hACE2 mice, albeit with some differences in activity and mechanisms of action. Although 214 AZD7442-TM had a limited protective effect on viral burden in the nasal washes and nasal 215 turbinates of infected mice, this was not entirely unexpected, as studies with the parental mAbs

COV2-2196 and COV2-2130 showed less protection in nasal washes than lungs against multiple
 SARS-CoV-2 VOC<sup>23</sup>. Moreover, studies in non-human primates with anti-SARS-CoV-2 human
 mAbs showed the concentrations in nasopharyngeal washes are approximately 0.1% of those
 found in the serum<sup>24</sup>, which likely explains their diminished benefit in this tissue compartment.

220 We also assessed whether the reductions in mAb neutralization potency against Omicron 221 variant strains correlated with the observed changes in viral burden. For AZD7442-TM, which contains L234F/L235E/P331S modifications that abolish Fc receptor engagement<sup>13</sup> and were 222 introduced to decrease the potential risk of antibody-dependent enhancement of disease<sup>18</sup>. 223 224 antibody-mediated reductions in viral titer corresponded directly with neutralization activity 225 against Omicron variant strains; thus, neutralization is likely a key protective mechanism for 226 these RBM-specific mAbs. For S309-LS, which only contains half-life extending M428L/N434S 227 modifications in the human IgG1 Fc domain, and exhibits Fc effector functions including ADCC 228 and ADCP<sup>11</sup>, changes in neutralization potency did not linearly relate to changes in lung viral 229 titer. S309-LS mAb treatment still conferred significant protection in the lungs of mice infected 230 with BA.2 despite a substantial loss in neutralizing activity. Because of these results, we 231 evaluated the contributions of Fc effector functions in protection in mice using S309-GRLR, which has G236R/L328R mutations in the Fc domain that abrogate binding to  $Fc\gamma Rs^{13}$ . We 232 233 observed that intact S309-LS but not S309-GRLR mAb protected K18-hACE2 and hFcyR mice 234 against SARS-CoV-2 variant strains. These results are consistent with prior studies showing a beneficial role of Fc-effector functions in antibody mediated protection in mice and hamsters<sup>25-</sup> 235 <sup>29</sup>, and may explain why mAbs with markedly different *in vitro* neutralization potencies against 236 237 SARS-CoV-2 activity similar protective in strains show animals 238 (https://opendata.ncats.nih.gov/covid19/animal). Furthermore, they also demonstrate that for

some mAbs, Fc effector functions can compensate for losses in neutralization potency against SARS-CoV-2 variants and act as a protective mechanism *in vivo*. Thus, effector functions can contribute to resilience of some mAbs against Omicron and other VOC<sup>30,31</sup>. We speculate that the stoichiometric threshold and antibody occupancy requirements for Fc effector function activity may be lower than for virion neutralization<sup>32</sup>; if so, this property might clarify how antibodies with reduced neutralizing potency against VOC that still bind spike protein on the virion or surface of infected cells retain protective activity *in vivo*.

246 Limitations of study. We note several limitations of our study: (a) Female K18-hACE2 247 mice were used to allow for group caging. Follow-up experiments in male mice to confirm and 248 extend these results are needed. (b) The BA.1, BA.1.1., and BA.2 viruses are less pathogenic in mice than the D614G virus<sup>16,33-35</sup>. This could lead to an overestimation of protection compared to 249 250 other more virulent strains in mice. (c) We only evaluated the efficacy of S309 or AZD7442 as 251 prophylaxis. Whereas AZD7442 is authorized only as preventive agent, post-exposure 252 therapeutic studies with both mAbs and Omicron variants may provide further insight as to 253 effects on potency. Moreover, the relationship between initial viral dosing and antibody 254 protection against Omicron variants was not explored. (d) Several experiments were performed 255 in transgenic mice that over-express human ACE2 receptors. High levels of cellular hACE2 can 256 diminish the neutralizing activity of mAbs that bind non-RBM sites of the SARS-CoV-2 spike<sup>36,37</sup>. Thus, studies in hACE2-transgenic mice could underestimate the efficacy of mAbs 257 258 binding outside of the RBM. Challenge studies in other animal models and ultimately humans 259 will be required for corroboration, including the contribution of Fc effector functions to mAb 260 efficacy.

261 Collectively, our data expand on recent *in vitro* findings with BA.1 strains by evaluating 262 the level of protection conferred by treatment with two EUA mAbs against the three currently 263 dominant Omicron variants. While S309-LS (and by extension Sotrovimab) and AZD7442-TM 264 (Evusheld) retained inhibitory activity against several Omicron lineage strains, the impact of 265 shifts in neutralization potency in vitro may not directly predict dosing in the clinical setting. 266 Finally, our studies highlight the potential of both mAb neutralization and Fc effector function 267 mechanisms in protecting against SARS-CoV-2-mediated disease and suggest mechanisms of 268 action for withstanding mutations in variant strains that reduce but do not abrogate mAb binding 269 and neutralization. 270

#### 272 ACKNOWLEDGEMENTS

This study was supported by grants and contracts from the NIH (R01 AI157155, U01
AI151810, NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contract
75N93019C00051) and the Defense Advanced Research Projects Agency (DARPA; HR001118-2-0001). J.B.C. is supported by a Helen Hay Whitney Foundation postdoctoral fellowship.
E.A.M. is supported by a W.M. Keck postdoctoral fellowship from Washington University. We
thank Gloria Lombardo and Selina Feller for technical support.

279

#### 280 AUTHOR CONTRIBUTIONS

281 J.B.C. performed and analyzed neutralization assays. J.M.E. performed structural analyses 282 with guidance from D.H.F. J.B.C., S.M., Z.C., and E.A.M. performed mouse experiments and 283 viral burden analyses. J.B.C. propagated and validated SARS-CoV-2 viruses. B.G. and M.A.S. 284 designed, performed, and analyzed *in vitro* Fc-mediated effector function studies. K. Rosenthal, 285 and K. Ren performed antibody analyses. A.J., L.D., and S.A.H. performed deep sequencing 286 analysis. L.A.P., D.C., Y-M.L., and M.T.E. provided mAbs. P.J.H. and Y.K. provided SARS-287 CoV-2 strains. J.E.C. and H.W.V. provided key intellectual contributions to the design of the 288 study D.H.F. and M.S.D. obtained funding and supervised the research. J.B.C. and M.S.D. wrote 289 the initial draft, with the other authors providing editorial comments.

290

#### 291 COMPETING FINANCIAL INTERESTS

M.S.D. is a consultant for Inbios, Vir Biotechnology, Senda Biosciences, and Carnival Corporation, and on the Scientific Advisory Boards of Moderna and Immunome. The Diamond laboratory has received funding support in sponsored research agreements from Moderna, Vir

295 Biotechnology, and Emergent BioSolutions. J.E.C. has served as a consultant for Luna 296 Innovations, Merck, and GlaxoSmithKline, is a member of the Scientific Advisory Board of 297 Meissa Vaccines and is founder of IDBiologics. The Crowe laboratory has received sponsored 298 research agreements from AstraZeneca, Takeda, and IDBiologics during the conduct of the 299 study. Vanderbilt University has applied for patents for some of the antibodies in this paper, for 300 which J.E.C. is an inventor. B.G., M.A.S, H.W.V., D.C., and L.A.P. are employees of Vir 301 Biotechnology and may hold equity in Vir Biotechnology. L.A.P. is a former employee and may 302 hold equity in Regeneron Pharmaceuticals. H.W.V. is a founder and holds shares in PierianDx 303 and Casma Therapeutics. Neither company provided resources to this study. Y.K. has received 304 unrelated funding support from Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns 305 Laboratories, Inc., Shionogi & Co. LTD, Otsuka Pharmaceutical, KM Biologics, Kyoritsu 306 Seiyaku, Shinya Corporation, and Fuji Rebio. K. Rosenthal, K. Ren, Y-M.L. and M.T.E. are 307 employees of AstraZeneca and may hold stock in AstraZeneca. All other authors declare no 308 competing financial interests.

309

#### 311 FIGURE LEGENDS

312 Figure 1. Neutralization of Omicron lineage strains by mAbs. a, One protomer of the 313 SARS-CoV-2 spike trimer (PDB: 7C2L) is depicted with BA.2 variant amino acid substitutions 314 labelled and shown as red spheres. The N-terminal domain (NTD), RBD, RBM, and S2 are 315 colored in yellow, green, magenta, and blue, respectively. All mutated residues in the BA.2 RBD 316 relative to WA1/2020 are indicated in **b**, and the BA.2 RBD bound by mAbs S309 (orange, 317 PDB: 6WPS) (b), AZD8895 (green, PDB: 7L7D) (c), and AZD1061 (purple, PDB:7L7E) (d) are 318 shown. BA.2 mutations in the respective epitopes of each mAb are shaded red, whereas those 319 outside the epitope are shaded green. e, Multiple sequence alignment showing the epitope 320 footprints of each mAb on the SARS-CoV-2 RBD (orange, S309; green, AZD8895; purple, 321 AZD1061). The WA1/2020 RBD is shown in the last row with relative variant sequence changes 322 indicated. Red circles below the sequence alignment indicate hACE2 contact residues on the SARS-CoV-2 RBD<sup>38</sup>. Structural analysis and depictions were generated using UCSF 323 ChimeraX<sup>39</sup>. **f-i**, Neutralization curves in Vero-TMPRSS2 cells with the indicated SARS-CoV-2 324 325 strain and mAb. The average of three to four experiments performed in technical duplicate are 326 shown. j-m, Comparison of EC<sub>50</sub> values for the indicated mAb against D614G, BA.1, BA.1.1, 327 and BA.2 viruses. Data are the average of three experiments, error bars indicate standard error of 328 the mean (SEM), and the dashed line indicates the upper limit of detection (one-way ANOVA with Dunnett's test; ns, not significant, \* P < 0.05, \*\* P < 0.01, \*\*\* P < 0.001, \*\*\*\* P < 0.001, \*\*\*\*\* P < 0.001, \*\*\*\* P < 0.001, \*\*\*\* P < 0.001, \*\*\*\*\* P < 0.001, 329 330 0.0001). **n**, Summary of the EC<sub>50</sub> values for each mAb against the indicated SARS-CoV-2 strain. 331 o, Summary of the fold-change in EC<sub>50</sub> values for each mAb against the indicated Omicron strain 332 relative to SARS-CoV-2 D614G.

333	Figure 2. Antibody protection against Omicron variants in K18-hACE2 mice. a-j,
334	Eight-week-old female K18-hACE2 mice received 200 µg (about 10 mg/kg) of the indicated
335	mAb treatment by intraperitoneal injection one day before intranasal inoculation with $10^3$ FFU of
336	the indicated SARS-CoV-2 strain. Tissues were collected at six (BA.2) or seven days (all other
337	strains) after inoculation. Viral RNA levels in the lungs (a, e), nasal turbinates (c, g), and nasal
338	washes ( <b>d</b> , <b>h</b> ) were determined by RT-qPCR, and infectious virus in the lungs ( <b>b</b> , <b>f</b> ) was assayed
339	by plaque assay (lines indicate median $\pm$ SEM.; n = 6-8 mice per group, two experiments; Mann-
340	Whitney test between isotype and mAb treatment; ns, not significant; * $P < 0.05$ , ** $P < 0.01$ ,
341	***, $P < 0.001$ ). i-j, Heat map of cytokine and chemokine protein expression levels in lung
342	homogenates from the indicated groups. Data are presented as log <sub>2</sub> -transformed fold-change over
343	naive mice. Blue, reduction; red, increase. k-l, Correlation analysis. The fold-change in $EC_{50}$
344	value of AZD7442-YTE/TM (k) and S309-LS (l) for D614G and each Omicron variant strain are
345	plotted on the x-axis. The fold-change in lung viral RNA titer between the respective isotype or
346	mAb-treated groups against each Omicron variant strain are plotted on the y-axis. Best-fit lines
347	were calculated using a simple linear regression. Two-tailed Pearson correlation was used to
348	calculate the R <sup>2</sup> and P values indicated within each panel.

**Figure 3. Role of Fc-effector functions in S309 mAb-mediated protection. a**, Binding of AZD7442-TM, S309-LS, or S309-GRLR mAbs to hFcγRI or hFcγRIIIa (two experiments; dotted lines indicate the limit of detection). **b**, ExpiCHO-S cells were transiently transfected with plasmids encoding the indicated SARS-CoV-2 spike protein. 24 to 48 h later, cells were harvested, washed, and stained with the indicated concentrations of VIR-7831 or S2X324 mAbs to assess binding to the cell surface. Representative histograms from two-three experiments are shown. **c**, ExpiCHO-S cells transiently transfected with Wuhan-1 D614, BA.1, or BA.2 spike

356 proteins were incubated with the indicated concentrations of VIR-7831 or S309-GRLR mAb and 357 mixed with purified NK cells isolated from healthy donors at a ratio of 1:9 (target:effector). Cell 358 lysis was determined by a lactate dehydrogenase release assay. The error bars indicate standard 359 deviations (SD). d, Area under the curve (AUC) analyses from four NK donors (Extended Data 360 Fig. 5). e, ExpiCHO-S cells transiently transfected with Wuhan-1 D614, BA.1, or BA.2 spike 361 proteins and fluorescently labelled with PKH67 were incubated with the indicated concentrations 362 of VIR-7831 or S309-GRLR mAb and mixed with PBMCs labelled with CellTrace Violet from 363 healthy donors at a ratio of 1:20 (target:PBMCs). Association of CD14<sup>+</sup> monocytes with spike-364 expressing target cells (ADCP) was determined by flow cytometry. The error bars indicate SD. f, 365 AUC analyses of VIR-7831 and S309-GRLR for each Omicron variant for four donors. (g-i) 366 Eight-week-old female K18-hACE2 mice or (j-k) 12-week-old male hFcyR mice received a 367 single 10 mg/kg or 3 mg/kg dose respectively, of S309-LS or S309-GRLR mAb by intraperitoneal injection one day before intranasal inoculation with 10<sup>3</sup> FFU of D614G, BA.1, or 368 BA.2 (g-i) or  $10^5$  FFU of Beta (B.1.351) (j-k). Tissues were collected at 2 (B.1.351), 4 (B.1.351), 369 370 6 (BA.2), or 7 (D614G and BA.1) dpi. Viral RNA levels in the lungs (g, j-k), nasal turbinates 371 (h), and nasal washes (i) were determined by RT-qPCR, and infectious virus in the lungs (j-k) 372 was measured by plaque assay (g-k; lines indicate median  $\pm$  SEM.; g-i and j-k; n = 8 and 373 10 mice per group, respectively; two experiments; g-i; (Mann-Whitney test between isotype and 374 mAb treatment; ns, not significant; \*\* P < 0.01, \*\*\*, P < 0.001); j-k; one-way ANOVA with 375 Tukey's multiple comparisons test; ns, not significant; \* P < 0.05, \*\* P < 0.01, \*\*\*, P < 0.001, \*\*\*\*, *P* < 0.0001). 376

377

#### 378 EXTENDED DATA FIGURES

#### **Extended Data Figure 1. BA.1.1 spike protein substitutions and mAb epitopes.** Mutated residues in the BA.1.1 RBD relative to WA1/2020 are indicated in green in all three panels. The BA.1.1 RBD bound by mAbs S309 (orange, PDB: 6WPS) (**a**), AZD8895 (pale green, PDB: 7L7D) (**b**), and AZD1061 (purple, PDB:7L7E) (**c**) are shown. BA.1.1 substitutions in the respective epitopes of each mAb are shaded red, whereas those outside the epitope are shaded green. Structural analysis and depictions were generated using UCSF ChimeraX<sup>39</sup>.

Extended Data Figure 2. Cytokine and chemokine induction after S309-LS treatment and SARS-CoV-2 infection. Individual graphs of cytokine and chemokine protein levels in the lungs of S309-LS mAb-treated K18-hACE2 mice at 6 (BA.2) or 7 dpi (all other strains) with the indicated SARS-CoV-2 strain (line indicates median; n = 3 naive, n = 6-8 for all other groups (Mann-Whitney test with comparison between the isotype control and mAb: \*, *P* < 0.05, \*\*, *P* < 0.01, \*\*\*, *P* < 0.001).

Extended Data Figure 3. Cytokine and chemokine induction after AZD7442-TM treatment and SARS-CoV-2 infection. Individual graphs of cytokine and chemokine protein levels in the lungs of AZD7442-TM mAb-treated K18-hACE2 mice at 6 (BA.2) or 7 dpi (all other strains) with the indicated SARS-CoV-2 strain (line indicates median; n = 3 naive, n = 8for all other groups (Mann-Whitney test with comparison between the isotype control and mAb: \*, P < 0.05, \*\*, P < 0.01, \*\*\*, P < 0.001).

397 Extended Data Figure 4. Neutralization of SARS-CoV-2 variants by S309-LS and 398 S309-GRLR mAbs. Neutralization curves in Vero-TMPRSS2 cells comparing infection of the 399 indicated SARS-CoV-2 strain in the presence of each mAb. The average of two experiments 400 performed in technical duplicate are shown. For D614G, BA.1, and BA.2 strains, the S309-LS 401 neutralization data from Fig. 1f are shown for comparison.

# 402 Extended Data Figure 5. VIR-7831-mediated antibody-dependent cell cytotoxicity 403 with NK cells. ExpiCHO-S cells transiently transfected with expression plasmids encoding 404 Wuhan D614, BA.1, or BA.2 spike proteins were incubated with the indicated concentrations of 405 VIR-7831 or S309-GRLR and mixed with NK cells isolated from healthy donors at a ratio of 1:9 406 (target:effector). Target cell lysis was determined by a lactate dehydrogenase release assay. The 407 error bars indicate SDs. Each panel is an individual donor. Donors 1 and 3 are heterozygous for 408 F158 and V158 FcγRIIIa, whereas donors 2 and 4 are homozygous for V158.

409 Extended Data Figure 6. VIR-7831-mediated antibody-dependent cell phagocytosis 410 with monocytes. ExpiCHO-S cells transiently transfected with Wuhan-1 D614, BA.1, or BA.2 411 spike proteins and fluorescently labelled with PKH67 were incubated with the indicated 412 concentrations of VIR-7831 or S309-GRLR mAb and mixed with PBMCs labelled with 413 CellTrace Violet from healthy donors carrying different FcyRIIA and IIIA genotypes at a ratio of 1:20 (target:PBMCs). Association of CD14<sup>+</sup> monocytes with spike-expressing target cells 414 415 (ADCP) was determined by flow cytometry. The error bars indicate SD. Each panel is an 416 individual donor.

## 417 Extended Data Figure 7. Gating strategy for CD14<sup>+</sup> monocytes used for antibody418 dependent cell phagocytosis assays. From PBMCs, monocytes were gated as CD3<sup>-</sup> CD19<sup>-</sup> 419 CD14<sup>+</sup> cells. For ADCP, % FITC<sup>+</sup> CellTrace Violet<sup>+</sup> CD14<sup>+</sup> monocytes were gated as indicated. 420 The gate of positive cells was set based on the no mAb control.

421

#### 422 SUPPLEMENTAL TABLE TITLES

423 Supplementary Table 1. Omicron variant strain mutations as determined by next424 generation sequencing.

#### 426 METHODS

427	Cells. Vero-TMPRSS2 <sup>40</sup> and Vero-hACE2-TMPRRS2 <sup>41</sup> cells were cultured at 37°C in
428	Dulbecco's Modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum
429	(FBS), 10□mM HEPES pH 7.3, 1□mM sodium pyruvate, 1× non-essential amino acids, and
430	100 $\square$ U/ml of penicillin–streptomycin. Vero-TMPRSS2 cells were supplemented with 5 µg/mL
431	of blasticidin. Vero-hACE2-TMPRSS2 cells were supplemented with 10 $\mu$ g/mL of puromycin.
432	ExpiCHO-S cells were obtained from Thermo Fisher Scientific. All cells routinely tested
433	negative for mycoplasma using a PCR-based assay.
434	Viruses. The Beta (B.1.351) and Omicron (BA.1 (R346), BA.1.1 (R346K), and BA.2)
435	strains were obtained from nasopharyngeal isolates. All virus stocks were generated in Vero-
436	TMPRSS2 cells and subjected to next-generation sequencing as described previously <sup>41</sup> to
437	confirm the presence and stability of expected substitutions (see Supplementary Table 1). All
438	virus experiments were performed in an approved biosafety level 3 (BSL-3) facility.
439	Monoclonal antibody purification. The mAbs studied in this paper, S309, AZD8895,
440	AZD1061, and the AZD7442 cocktail have been described previously <sup>4,11,18</sup> .
441	S309-LS and S309-GRLR were produced in ExpiCHO-S cells and affinity-purified using
442	HiTrap Protein A columns (GE Healthcare, HiTrap mAb select Xtra #28-4082-61) followed by
443	buffer exchange to histidine buffer (20 mM histidine, 8% sucrose, pH 6.0) using HiPrep 26/10
444	desalting columns. The final products were sterilized after passage through 0.22 $\mu$ m filters and

445 stored at 4°C. VIR-7831 (clinical lead variant of S309-LS) was produced at WuXi Biologics.

446 AZD8895 and AZD1061 mAbs were cloned into mammalian expression vectors and 447 expressed as IgG1 constructs with the TM (L234F/L235E/P331S) Fc modification with or 448 without a second YTE (M252Y/S254T/T256E) modification to extend half-life in humans.

MAbs were expressed in 293F cells after transfection with 293fectin (Thermo Fisher Scientific)
and isolated from supernatants by affinity chromatography using Protein A or Protein G columns
(GE Healthcare). MAbs were eluted with 0.1 M glycine at low pH and dialyzed into PBS.

452 **Mouse experiments.** Animal studies were carried out in accordance with the 453 recommendations in the Guide for the Care and Use of Laboratory Animals of the National 454 Institutes of Health. The protocols were approved by the Institutional Animal Care and Use 455 Committee at the Washington University School of Medicine (assurance number A3381–01). 456 Virus inoculations were performed under anesthesia that was induced and maintained with 457 ketamine hydrochloride and xylazine, and all efforts were made to minimize animal suffering.

458 Heterozygous K18-hACE2 C57BL/6J mice (strain: 2B6.Cg-Tg(K18-ACE2)2Prlmn/J) 459 and wild-type C57BL/6J (strain: 000664) mice were obtained from The Jackson Laboratory. mice<sup>20</sup>  $(Fc\gamma R\alpha^{-/-})$ 460 Human FcyR transgenic  $/hFc\gamma RII^{+}/hFc\gamma RIIA^{R131+}/hFc\gamma RIIB^{+}/hFc\gamma RIIIA^{F158+}/hFc\gamma RIIIB^{+})$  were a generous gift (J. 461 462 Ravetch, Rockefeller University) and bred at Washington University. All animals were housed in 463 groups and fed standard chow diets. For experiments with K18-hACE2 mice, eight- to ten-week-464 old female mice were administered the indicated doses of the respective SARS-CoV-2 strains 465 (see Figure legends) by intranasal administration. For hFcyR mouse experiments, 12-week-old male mice were administered  $10^5$  FFU of a Beta (B.1.351) isolate by intranasal administration. In 466 467 vivo studies were not blinded, and mice were randomly assigned to treatment groups. No sample-468 size calculations were performed to power each study. Instead, sample sizes were determined 469 based on prior *in vivo* virus challenge experiments. Mice were administered the indicated mAb 470 dose by intraperitoneal injection one day before intranasal inoculation with the indicated SARS-

471 CoV-2 strain. AZD7442-TM (lacking the YTE modification that accelerates antibody
472 elimination in rodents) was used in mouse studies.

Focus reduction neutralization test. Serial dilutions of mAbs were incubated with  $10^2$ 473 474 focus-forming units (FFU) of different strains or variants of SARS-CoV-2 for 1 h at 37°C. 475 Antibody-virus complexes were added to Vero-TMPRSS2 cell monolayers in 96-well plates and 476 incubated at 37°C for 1 h. Subsequently, cells were overlaid with 1% (w/v) methylcellulose in 477 MEM. Plates were harvested 48-72 h later by removing overlays and fixing with 4% PFA in PBS 478 for 20 min at room temperature. Plates were washed and incubated with an oligoclonal pool of SARS2-2, SARS2-11, SARS2-16, SARS2-31, SARS2-38, SARS2-57, and SARS2-71<sup>42</sup>. Plates 479 480 with Omicron variant strains were additionally incubated with CR3022 and a pool of anti-SARS-CoV-2 mAbs that cross-react with SARS-CoV<sup>43</sup>. Subsequently, samples were incubated 481 482 with HRP-conjugated goat anti-mouse IgG (Sigma, 12-349) and HRP-conjugated goat anti-483 human IgG (Sigma, A6029) in PBS supplemented with 0.1% saponin and 0.1% bovine serum 484 albumin. SARS-CoV-2-infected cell foci were visualized using TrueBlue peroxidase substrate 485 (KPL) and quantitated on an ImmunoSpot microanalyzer (Cellular Technologies).

486 Measurement of viral RNA levels. Tissues were weighed and homogenized with 487 zirconia beads in a MagNA Lyser instrument (Roche Life Science) in 1 mL of DMEM medium 488 supplemented with 2% heat-inactivated FBS. Tissue homogenates were clarified by 489 centrifugation at 10,000 rpm for 5 min and stored at -80°C. RNA was extracted using the 490 MagMax mirVana Total RNA isolation kit (Thermo Fisher Scientific) on the Kingfisher Flex 491 extraction robot (Thermo Fisher Scientific). RNA was reverse transcribed and amplified using 492 the TaqMan RNA-to-CT 1-Step Kit (Thermo Fisher Scientific). Reverse transcription was 493 carried out at 48°C for 15 min followed by 2 min at 95°C. Amplification was accomplished over

494 50 cycles as follows: 95°C for 15 s and 60°C for 1 min. Copies of SARS-CoV-2 N gene RNA in 495 samples were determined using a previously published assay<sup>44</sup>. Briefly, a TaqMan assay was 496 designed to target a highly conserved region of the N gene (Forward primer: 497 ATGCTGCAATCGTGCTACAA; Reverse primer: GACTGCCGCCTCTGCTC; Probe: /56-498 FAM/TCAAGGAAC/ZEN/AACATTGCCAA/3IABkFQ/). This region was included in an RNA 499 standard to allow for copy number determination down to 10 copies per reaction. The reaction 500 mixture contained final concentrations of primers and probe of 500 and 100 nM, respectively.

501 **Viral plaque assay.** Vero-TMPRSS2-hACE2 cells were seeded at a density of  $1 \times 10^5$ 502 cells per well in 24-well tissue culture plates. The following day, medium was removed and 503 replaced with 200 µL of material to be titrated diluted serially in DMEM supplemented with 2% 504 FBS. One hour later, 1 mL of methylcellulose overlay was added. Plates were incubated for 72 h, 505 then fixed with 4% paraformaldehyde (final concentration) in PBS for 20 min. Plates were 506 stained with 0.05% (w/v) crystal violet in 20% methanol and washed twice with distilled, 507 deionized water.

508 Transient expression of recombinant SARS-CoV-2 protein and flow cytometry. ExpiCHO-S cells were seeded at 6 x  $10^6$  cells/mL in a volume of 5 mL in a 50 mL bioreactor. 509 510 The following day, cells were transfected with SARS-CoV-2 spike glycoprotein-encoding 511 pcDNA3.1(+) plasmids (BetaCoV/Wuhan-Hu-1/2019, accession number MN908947, Wuhan 512 D614; Omicron BA.1 and BA.2 generated by overlap PCR mutagenesis of the Wuhan D614 plasmid) harboring the  $\Delta 19$  C-terminal truncation<sup>26</sup>. Spike encoding plasmids were diluted in 513 514 cold OptiPRO SFM (Life Technologies, 12309-050), mixed with ExpiFectamine CHO Reagent 515 (Life Technologies, A29130) and added to cells. Transfected cells were then incubated at 37°C 516 with 8% CO<sub>2</sub> with an orbital shaking speed of 250 RPM (orbital diameter of 25 mm) for 24 to 48

517 h. Transiently transfected ExpiCHO-S cells were harvested and washed twice in wash buffer 518 (PBS 2% FBS, 2 mM EDTA). Cells were counted and distributed into round bottom 96-well 519 plates (Corning, 3799) and incubated with serial dilutions of mAb starting at 10  $\mu$ g/mL. Alexa 520 Fluor647-labelled Goat Anti-human IgG secondary Ab (Jackson Immunoresearch, 109-606-098) 521 was prepared at 2  $\mu$ g/mL and added onto cells after two washing steps. Cells were then washed 522 twice and resuspended in wash buffer for data acquisition at ZE5 cytometer (BioRad).

523 Fc-mediated effector functions. Primary cells were collected from healthy human 524 donors with informed consent and authorization via the Comitato Etico Canton Ticino 525 (Switzerland). ADCC assays were performed using ExpiCHO-S cells transiently transfected with 526 SARS-CoV-2 spike glycoproteins (Wuhan D614, BA.1 or BA.2) as targets. NK cells were 527 isolated from fresh blood of healthy donors using the MACSxpress NK Isolation Kit (Miltenyi 528 Biotec, cat. no. 130-098-185). Target cells were incubated with titrated concentrations of mAbs 529 for 10 min and then with primary human NK cells at an effector:target ratio of 9:1. ADCC was 530 measured using LDH release assay (Cytotoxicity Detection Kit (LDH) (Roche; cat. no. 531 11644793001) after 4 h incubation at 37°C.

532 ADCP assays were performed using ExpiCHO-S cells transiently transfected with SARS-533 CoV-2 spike glycoproteins (Wuhan D614, BA.1, or BA.2) and labelled with PKH67 (Sigma 534 Aldrich) as targets. PMBCs from healthy donors were labelled with CellTrace Violet 535 (Invitrogen) and used as source of phagocytic effector cells. Target cells (10,00 per well) were 536 incubated with titrated concentrations of mAbs for 10 min and then mixed with PBMCs (200,000 537 per well). The next day, cells were stained with APC-labelled anti-CD14 mAb (BD Pharmingen), 538 BV605-labelled anti-CD16 mAb (Biolegend), BV711-labelled anti-CD19 mAb (Biolegend), 539 PerCP/Cy5.5-labelled anti-CD3 mAb (Biolegend), APC/Cy7-labelled anti-CD56 mAb

(Biolegend) for the identification of CD14<sup>+</sup> monocytes. After 20 min, cells were washed and
fixed with 4% paraformaldehyde before acquisition on a ZE5 Cell Analyzer (Biorad). Data were
analyzed using FlowJo software. The % ADCP was calculated as % of monocytes (CD3<sup>-</sup> CD19<sup>-</sup>
CD14<sup>+</sup> cells) positive for PKH67.

544 **Data availability.** All data supporting the findings of this study are available within the 545 paper and are available from the corresponding author upon request.


546 **Statistical analysis**. All statistical tests were performed as described in the indicated 547 figure legends using Prism 8.0. Statistical significance was determined using a one-way ANOVA 548 when comparing three or more groups. When comparing two groups, a Mann-Whitney test was 549 performed. The number of independent experiments performed are indicated in the relevant 550 figure legends. For correlation analyses, best-fit lines were calculated using a simple linear 551 regression. Two-tailed Pearson correlation was used to calculate the R<sup>2</sup> and P values indicated 552 within each panel.

#### 554 **REFERENCES**

- 555
- VanBlargan, L. A. *et al.* An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes
   neutralization by therapeutic monoclonal antibodies. *Nat Med*, doi:10.1038/s41591-021 01678-y (2022).
- Liu, L. *et al.* Striking antibody evasion manifested by the Omicron variant of SARS CoV-2. *Nature*, doi:10.1038/s41586-021-04388-0 (2021).
- 561 3 McCallum, M. *et al.* Structural basis of SARS-CoV-2 Omicron immune evasion and 562 receptor engagement. *Science* **375**, 864-868, doi:10.1126/science.abn8652 (2022).
- 5634Cameroni, E. *et al.* Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron564antigenic shift. *Nature* 602, 664-670, doi:10.1038/s41586-021-04386-2 (2022).
- 565 5 Iketani, S. *et al.* Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages.
   566 *bioRxiv*, doi:10.1101/2022.02.07.479306 (2022).
- 5676Dejnirattisai, W. et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from568neutralizing antibody responses. Cell 185, 467-484 e415, doi:10.1016/j.cell.2021.12.046569(2022).
- 570 7 DiLillo, D. J., Palese, P., Wilson, P. C. & Ravetch, J. V. Broadly neutralizing antiinfluenza antibodies require Fc receptor engagement for in vivo protection. *J Clin Invest* 572 **126**, 605-610, doi:10.1172/jci84428 (2016).
- 573 8 DiLillo, D. J., Tan, G. S., Palese, P. & Ravetch, J. V. Broadly neutralizing hemagglutinin
  574 stalk-specific antibodies require FcγR interactions for protection against influenza virus
  575 in vivo. *Nat Med* 20, 143-151, doi:10.1038/nm.3443 (2014).
- 576 9 Gunn, B. M. *et al.* A Role for Fc Function in Therapeutic Monoclonal Antibody577 Mediated Protection against Ebola Virus. *Cell Host Microbe* 24, 221-233.e225,
  578 doi:10.1016/j.chom.2018.07.009 (2018).
- 579 10 Saphire, E. O. *et al.* Systematic Analysis of Monoclonal Antibodies against Ebola Virus
  580 GP Defines Features that Contribute to Protection. *Cell* 174, 938-952.e913,
  581 doi:10.1016/j.cell.2018.07.033 (2018).
- 58211Pinto, D. *et al.* Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV583antibody. *Nature* 583, 290-295, doi:10.1038/s41586-020-2349-y (2020).
- 58412Zost, S. J. *et al.* Potently neutralizing and protective human antibodies against SARS-585CoV-2. Nature 584, 443-449, doi:10.1038/s41586-020-2548-6 (2020).
- Saunders, K. O. Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. *Frontiers in Immunology* 10, doi:10.3389/fimmu.2019.01296 (2019).
- Acqua, W. F. D. *et al.* Increasing the Affinity of a Human IgG1 for the Neonatal Fc
  Receptor: Biological Consequences. *The Journal of Immunology* 169, 5171,
  doi:10.4049/jimmunol.169.9.5171 (2002).
- Halfmann, P. J. *et al.* SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. *Nature*, doi:10.1038/s41586-022-04441-6 (2022).
- Halfmann, P. J. *et al.* SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. *Nature*, doi:10.1038/s41586-022-04441-6 (2022).
- 596 17 Dong, J. *et al.* Genetic and structural basis for SARS-CoV-2 variant neutralization by a
  597 two-antibody cocktail. *Nat Microbiol* 6, 1233-1244, doi:10.1038/s41564-021-00972-2
  598 (2021).

- Loo, Y. M. *et al.* The SARS-CoV-2 monoclonal antibody combination, AZD7442, is
  protective in non-human primates and has an extended half-life in humans. *Sci Transl Med*, eabl8124, doi:10.1126/scitranslmed.abl8124 (2022).
- 602 19 Oganesyan, V., Gao, C., Shirinian, L., Wu, H. & Dall'Acqua, W. F. Structural
  603 characterization of a human Fc fragment engineered for lack of effector functions. *Acta*604 *Crystallogr D Biol Crystallogr* 64, 700-704, doi:10.1107/S0907444908007877 (2008).
- 605 20 Smith, P., DiLillo, D. J., Bournazos, S., Li, F. & Ravetch, J. V. Mouse model
  606 recapitulating human Fcγ receptor structural and functional diversity. *Proc Natl Acad Sci*607 US A 109, 6181-6186, doi:10.1073/pnas.1203954109 (2012).
- Tatham, L. *et al.* Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab)
  virological efficacy against the SARS-CoV-2 Omicron variant (B.1.1.529) in K18hACE2 mice. *bioRxiv*, doi:10.1101/2022.01.23.477397 (2022).
- 611 22 Westendorf, K. *et al.* LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2
  612 variants. *bioRxiv*, doi:10.1101/2021.04.30.442182 (2021).
- 613 23 Chen, R. E. *et al.* In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. *Nature* 596, 103-108, doi:10.1038/s41586-021-03720-y (2021).
- 615 24 Cobb, R. R. *et al.* A combination of two human neutralizing antibodies prevents SARS616 CoV-2 infection in cynomolgus macaques. *Med (N Y)*, doi:10.1016/j.medj.2022.01.004
  617 (2022).
- 618 25 Beaudoin-Bussières, G. *et al.* A Fc-enhanced NTD-binding non-neutralizing antibody
  619 delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2
  620 infection. *Cell Rep* 38, 110368, doi:10.1016/j.celrep.2022.110368 (2022).
- 621 26 Ou, X. *et al.* Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
  622 its immune cross-reactivity with SARS-CoV. *Nature Communications* 11, 1620,
  623 doi:10.1038/s41467-020-15562-9 (2020).
- Schäfer, A. et al. Antibody potency, effector function, and combinations in protection 624 27 625 SARS-CoV-2 infection therapy for in vivo. J Exp Med 218. and doi:10.1084/jem.20201993 (2021). 626
- 627 28 Ullah, I. *et al.* Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing
  628 antibodies require Fc function for optimal efficacy. *Immunity* 54, 2143-2158.e2115,
  629 doi:10.1016/j.immuni.2021.08.015 (2021).
- Yamin, R. *et al.* Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2
  efficacy. *Nature* 599, 465-470, doi:10.1038/s41586-021-04017-w (2021).
- Grunst, M. W. & Uchil, P. D. Fc effector cross-reactivity: A hidden arsenal against
  SARS-CoV-2's evasive maneuvering. *Cell Rep Med* 3, 100540,
  doi:10.1016/j.xcrm.2022.100540 (2022).
- 63531Richardson, S. I. et al. SARS-CoV-2 Beta and Delta variants trigger Fc effector function636with increased cross-reactivity.Cell Rep Med 3, 100510,637doi:10.1016/j.xcrm.2022.100510 (2022).
- Bierson, T. C. & Diamond, M. S. A game of numbers: the stoichiometry of antibodymediated neutralization of flavivirus infection. *Prog Mol Biol Transl Sci* 129, 141-166,
  doi:10.1016/bs.pmbts.2014.10.005 (2015).
- Kawaoka, Y. *et al.* Characterization and antiviral susceptibility of SARS-CoV-2
  Omicron/BA.2. *Res Sq*, doi:10.21203/rs.3.rs-1375091/v1 (2022).

- 643 34 Bentley, E. G. *et al.* SARS-CoV-2 Omicron-B. 1.1. 529 Variant leads to less severe
  644 disease than Pango B and Delta variants strains in a mouse model of severe COVID-19.
  645 *bioRxiv* (2021).
- 646 35 Abdelnabi, R. *et al.* The omicron (B. 1.1. 529) SARS-CoV-2 variant of concern does not 647 readily infect Syrian hamsters. *Antiviral Research*, 105253 (2022).
- 64836Lempp, F. A. *et al.* Lectins enhance SARS-CoV-2 infection and influence neutralizing649antibodies. *Nature* **598**, 342-347, doi:10.1038/s41586-021-03925-1 (2021).
- Suryadevara, N. *et al.* Neutralizing and protective human monoclonal antibodies
  recognizing the N-terminal domain of the SARS-CoV-2 spike protein. *Cell* 184, 23162331.e2315, doi:10.1016/j.cell.2021.03.029 (2021).
- 65338Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the654ACE2 receptor. Nature **581**, 215-220, doi:10.1038/s41586-020-2180-5 (2020).
- 655 39 Goddard, T. D. *et al.* UCSF ChimeraX: Meeting modern challenges in visualization and analysis. *Protein Science* **27**, 14-25, doi:10.1002/pro.3235 (2018).
- 65740Zang, R. *et al.* TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human658small intestinal enterocytes. *Sci Immunol* 5, doi:10.1126/sciimmunol.abc3582 (2020).
- 659 41 Chen, R. E. *et al.* Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. *Nat Med*, doi:10.1038/s41591-021-01294-w (2021).
- Liu, Z. *et al.* Identification of SARS-CoV-2 spike mutations that attenuate monoclonal
  and serum antibody neutralization. *Cell Host Microbe* 29, 477-488.e474,
  doi:10.1016/j.chom.2021.01.014 (2021).
- VanBlargan, L. A. *et al.* A potently neutralizing SARS-CoV-2 antibody inhibits variants
  of concern by utilizing unique binding residues in a highly conserved epitope. *Immunity*54, 2399-2416.e2396, doi:10.1016/j.immuni.2021.08.016 (2021).
- Case, J. B., Bailey, A. L., Kim, A. S., Chen, R. E. & Diamond, M. S. Growth, detection,
  quantification, and inactivation of SARS-CoV-2. *Virology* 548, 39-48,
  doi:10.1016/j.virol.2020.05.015 (2020).
- 672



S309

AZD8895

AZD1061

AZD7442

2.4

117.6

206.1

25.5

\_

-

mAb	D614G	BA.1	BA.1.1	BA.2
S309	185.2	452.0	717.4	5,885.0
AZD8895	5.4	635.0	686.2	364.7
AZD1061	29.5	6,078.7	> 50,000	32.0
AZD7442	6.5	166.6	1,146.8	35.4

#### Figure 1

31.8

67.5

1.1

5.4

3.9

127.1

> 1,694

175.9

